Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.
Identifieur interne : 000585 ( PubMed/Checkpoint ); précédent : 000584; suivant : 000586Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.
Auteurs : Kaylena A. Ehgoetz Martens [Canada] ; Colin G. Ellard [Canada] ; Quincy J. Almeida [Canada]Source :
- The European journal of neuroscience [ 1460-9568 ] ; 2015.
English descriptors
- KwdEn :
- Aged, Anxiety (complications), Anxiety (diagnosis), Anxiety (etiology), Biomechanical Phenomena, Case-Control Studies, Dihydroxyphenylalanine (therapeutic use), Dopamine Agents (therapeutic use), Female, Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (etiology), Galvanic Skin Response, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Self Report, User-Computer Interface.
- MESH :
- chemical , therapeutic use : Dihydroxyphenylalanine, Dopamine Agents.
- complications : Anxiety, Parkinson Disease.
- diagnosis : Anxiety.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Anxiety, Gait Disorders, Neurologic.
- Aged, Biomechanical Phenomena, Case-Control Studies, Female, Galvanic Skin Response, Humans, Male, Middle Aged, Self Report, User-Computer Interface.
Abstract
In order to understand how dopamine modulates the effect of anxiety on gait, the goal of this study was to use virtual reality to provoke anxiety in Parkinson's disease (PD) (in both ON and OFF states) and quantify its effect on gait. Seventeen participants with PD and 20 healthy age-matched controls were instructed to walk in a virtual environment in two anxiety-provoking conditions: (i) across a plank that was located on the GROUND and (ii) across an ELEVATED plank. All participants with PD completed this experiment in both the ON and OFF states, and were then striated into groups based on baseline trait anxiety scores for further analyses. Anxiety (skin conductance and self-report) and spatiotemporal aspects of gait were measured. Overall, the ELEVATED condition resulted in greater skin conductance levels and self-reported anxiety levels. Additionally, all participants demonstrated slower gait with increased step-to-step variability when crossing the ELEVATED plank compared with the plank on the GROUND. The results showed that dopaminergic treatment selectively improved gait in only the highly anxious PD group, by significantly improving velocity, step length, step time and step-to-step variability specifically when walking across the ELEVATED plank (ON vs. OFF comparison). In conclusion, only highly trait anxious participants with PD benefitted from dopaminergic treatment, specifically when walking in the anxiety-provoking environment. Improvements to gait during anxious walking might be a result of dopaminergic medication acting in two ways: (i) improving the basal ganglia's capacity to process information and (ii) reducing the load from anxiety and subsequently making more resources available to effectively process other competing inputs.
DOI: 10.1111/ejn.12928
PubMed: 25899750
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25899750Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.</title><author><name sortKey="Ehgoetz Martens, Kaylena A" sort="Ehgoetz Martens, Kaylena A" uniqKey="Ehgoetz Martens K" first="Kaylena A" last="Ehgoetz Martens">Kaylena A. Ehgoetz Martens</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5</wicri:regionArea><wicri:noRegion>ON N2L 3C5</wicri:noRegion></affiliation></author><author><name sortKey="Ellard, Colin G" sort="Ellard, Colin G" uniqKey="Ellard C" first="Colin G" last="Ellard">Colin G. Ellard</name><affiliation wicri:level="1"><nlm:affiliation>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Almeida, Quincy J" sort="Almeida, Quincy J" uniqKey="Almeida Q" first="Quincy J" last="Almeida">Quincy J. Almeida</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5</wicri:regionArea><wicri:noRegion>ON N2L 3C5</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25899750</idno><idno type="pmid">25899750</idno><idno type="doi">10.1111/ejn.12928</idno><idno type="wicri:Area/PubMed/Corpus">000451</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000451</idno><idno type="wicri:Area/PubMed/Curation">000451</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000451</idno><idno type="wicri:Area/PubMed/Checkpoint">000451</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000451</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.</title><author><name sortKey="Ehgoetz Martens, Kaylena A" sort="Ehgoetz Martens, Kaylena A" uniqKey="Ehgoetz Martens K" first="Kaylena A" last="Ehgoetz Martens">Kaylena A. Ehgoetz Martens</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5</wicri:regionArea><wicri:noRegion>ON N2L 3C5</wicri:noRegion></affiliation></author><author><name sortKey="Ellard, Colin G" sort="Ellard, Colin G" uniqKey="Ellard C" first="Colin G" last="Ellard">Colin G. Ellard</name><affiliation wicri:level="1"><nlm:affiliation>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Almeida, Quincy J" sort="Almeida, Quincy J" uniqKey="Almeida Q" first="Quincy J" last="Almeida">Quincy J. Almeida</name><affiliation wicri:level="1"><nlm:affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5</wicri:regionArea><wicri:noRegion>ON N2L 3C5</wicri:noRegion></affiliation></author></analytic><series><title level="j">The European journal of neuroscience</title><idno type="eISSN">1460-9568</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anxiety (complications)</term><term>Anxiety (diagnosis)</term><term>Anxiety (etiology)</term><term>Biomechanical Phenomena</term><term>Case-Control Studies</term><term>Dihydroxyphenylalanine (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (etiology)</term><term>Galvanic Skin Response</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Self Report</term><term>User-Computer Interface</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dihydroxyphenylalanine</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anxiety</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Anxiety</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anxiety</term><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Biomechanical Phenomena</term><term>Case-Control Studies</term><term>Female</term><term>Galvanic Skin Response</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Self Report</term><term>User-Computer Interface</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to understand how dopamine modulates the effect of anxiety on gait, the goal of this study was to use virtual reality to provoke anxiety in Parkinson's disease (PD) (in both ON and OFF states) and quantify its effect on gait. Seventeen participants with PD and 20 healthy age-matched controls were instructed to walk in a virtual environment in two anxiety-provoking conditions: (i) across a plank that was located on the GROUND and (ii) across an ELEVATED plank. All participants with PD completed this experiment in both the ON and OFF states, and were then striated into groups based on baseline trait anxiety scores for further analyses. Anxiety (skin conductance and self-report) and spatiotemporal aspects of gait were measured. Overall, the ELEVATED condition resulted in greater skin conductance levels and self-reported anxiety levels. Additionally, all participants demonstrated slower gait with increased step-to-step variability when crossing the ELEVATED plank compared with the plank on the GROUND. The results showed that dopaminergic treatment selectively improved gait in only the highly anxious PD group, by significantly improving velocity, step length, step time and step-to-step variability specifically when walking across the ELEVATED plank (ON vs. OFF comparison). In conclusion, only highly trait anxious participants with PD benefitted from dopaminergic treatment, specifically when walking in the anxiety-provoking environment. Improvements to gait during anxious walking might be a result of dopaminergic medication acting in two ways: (i) improving the basal ganglia's capacity to process information and (ii) reducing the load from anxiety and subsequently making more resources available to effectively process other competing inputs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25899750</PMID><DateCreated><Year>2015</Year><Month>08</Month><Day>17</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-9568</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The European journal of neuroscience</Title><ISOAbbreviation>Eur. J. Neurosci.</ISOAbbreviation></Journal><ArticleTitle>Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>2028-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejn.12928</ELocationID><Abstract><AbstractText>In order to understand how dopamine modulates the effect of anxiety on gait, the goal of this study was to use virtual reality to provoke anxiety in Parkinson's disease (PD) (in both ON and OFF states) and quantify its effect on gait. Seventeen participants with PD and 20 healthy age-matched controls were instructed to walk in a virtual environment in two anxiety-provoking conditions: (i) across a plank that was located on the GROUND and (ii) across an ELEVATED plank. All participants with PD completed this experiment in both the ON and OFF states, and were then striated into groups based on baseline trait anxiety scores for further analyses. Anxiety (skin conductance and self-report) and spatiotemporal aspects of gait were measured. Overall, the ELEVATED condition resulted in greater skin conductance levels and self-reported anxiety levels. Additionally, all participants demonstrated slower gait with increased step-to-step variability when crossing the ELEVATED plank compared with the plank on the GROUND. The results showed that dopaminergic treatment selectively improved gait in only the highly anxious PD group, by significantly improving velocity, step length, step time and step-to-step variability specifically when walking across the ELEVATED plank (ON vs. OFF comparison). In conclusion, only highly trait anxious participants with PD benefitted from dopaminergic treatment, specifically when walking in the anxiety-provoking environment. Improvements to gait during anxious walking might be a result of dopaminergic medication acting in two ways: (i) improving the basal ganglia's capacity to process information and (ii) reducing the load from anxiety and subsequently making more resources available to effectively process other competing inputs.</AbstractText><CopyrightInformation>© 2015 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ehgoetz Martens</LastName><ForeName>Kaylena A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellard</LastName><ForeName>Colin G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience, Department of Psychology, University of Waterloo, Waterloo, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Quincy J</ForeName><Initials>QJ</Initials><AffiliationInfo><Affiliation>Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, 75 University Avenue West Waterloo, ON N2L 3C5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Neurosci</MedlineTA><NlmUniqueID>8918110</NlmUniqueID><ISSNLinking>0953-816X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004295" MajorTopicYN="N">Dihydroxyphenylalanine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005712" MajorTopicYN="N">Galvanic Skin Response</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">dopaminergic replacement therapy</Keyword><Keyword MajorTopicYN="N">gait</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">virtual reality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25899750</ArticleId><ArticleId IdType="doi">10.1111/ejn.12928</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Ehgoetz Martens, Kaylena A" sort="Ehgoetz Martens, Kaylena A" uniqKey="Ehgoetz Martens K" first="Kaylena A" last="Ehgoetz Martens">Kaylena A. Ehgoetz Martens</name></noRegion><name sortKey="Almeida, Quincy J" sort="Almeida, Quincy J" uniqKey="Almeida Q" first="Quincy J" last="Almeida">Quincy J. Almeida</name><name sortKey="Ellard, Colin G" sort="Ellard, Colin G" uniqKey="Ellard C" first="Colin G" last="Ellard">Colin G. Ellard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000585 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000585 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25899750
|texte= Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25899750" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |